Zhang J Y, Liu Y X, Wang H, Mi L, Song G H, Jiang H F, Yan Y, Shao B, Kong W Y, Zhang R Y, Ran R, Liu X R, Wang J, Lin Y T, Li H P
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhonghua Yi Xue Za Zhi. 2018 Sep 11;98(34):2718-2721. doi: 10.3760/cma.j.issn.0376-2491.2018.34.008.
To investigate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving docetaxel as adjuvant chemotherapy. A total of 58 patients with breast cancer receiving adjuvant chemotherapy with docetaxel were included between January 2014 to October 2017. Prophylactic use of PEG-rhG-CSF was administered.Patients were further divided into two groups according to the frequency of PEG-rhG-CSF use: frequent use group (≥3 cycles) and non-frequent use group (<3 cycles). There were significant differences in the incidence rates of grade 3/4 neutropenia between the prophylactic group and non-prophylactic group in cycle 1-3(<0.05). Less febrile neutropenia (FN) was also noted in the prophylactic group compared with the non-prophylactic group in cycle 1 and cycle 3 (<0.05). Grade 3/4 neutropenia and FN were less in the frequent use of group compared with the non-frequent use group(<0.001). The most common side effects of PEG-rhG-CSF included fatigue (10.2%), bone joint pain(50.8%), and 2 patients (3.4%) refused further treatment because of bone joint pain. PEG-rhG-CSF should be prophylactically used for preventing neutropenia and febrile neutropenia in breast cancer patients receiving adjuvant chemotherapy with docetaxel regimen.
探讨聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）预防性应用于接受多西他赛辅助化疗的乳腺癌患者的疗效和安全性。纳入2014年1月至2017年10月期间共58例接受多西他赛辅助化疗的乳腺癌患者，给予PEG-rhG-CSF预防性应用。根据PEG-rhG-CSF使用频率将患者进一步分为两组：频繁使用组（≥3个周期）和非频繁使用组（<3个周期）。在第1-3周期，预防性使用组和未预防性使用组之间3/4级中性粒细胞减少的发生率存在显著差异（<0.05）。在第1周期和第3周期，预防性使用组的发热性中性粒细胞减少（FN）也比未预防性使用组少（<0.05）。频繁使用组的3/4级中性粒细胞减少和FN比非频繁使用组少（<0.001）。PEG-rhG-CSF最常见的副作用包括疲劳（10.2%）、骨关节疼痛（50.8%），2例患者（3.4%）因骨关节疼痛拒绝进一步治疗。PEG-rhG-CSF应预防性用于预防接受多西他赛方案辅助化疗的乳腺癌患者的中性粒细胞减少和发热性中性粒细胞减少。
